Tokyo Tape
Sign in
← Suzuken

Quarterly report · Q2

9987.TEDINET S100PLBR
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.14T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.10T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥14.9bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥7.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥16.7bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥8.8bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥16.5bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥13.4bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥10.8bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥9.2bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥10.8bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥9.2bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.19Tat 2022-09-30Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.16Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥764.4bnat 2022-09-30Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥429.1bnat 2022-09-30Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥422.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥132.9bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥155.8bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥168.2bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥159.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥168.8bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥28.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥9.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥15.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥37.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥1.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥17.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥11.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥7.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥123.362022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.862022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥103.752021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥108.922021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio35.9%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥107.1bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥19.9bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥87.2bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥930m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥43.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥43.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥644m
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.07T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥25.1bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.1bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥22.7bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.5bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥17.2bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.27T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.14T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥129.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥14.7bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥85.3bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥19.4bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥65.9bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥13m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.0bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.06T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.03T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥25.8bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥3.5bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥21.9bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥6.0bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥15.9bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.21T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.10T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥107.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥7.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
LiabilitiesCurrentQuarterInstant764369000000JPY
Capital stockPrior1YearInstant13546000000JPY
Capital stockCurrentQuarterInstant13546000000JPY
Capital surplusPrior1YearInstant39337000000JPY
Capital surplusCurrentQuarterInstant39334000000JPY
Retained earningsPrior1YearInstant394296000000JPY
Retained earningsCurrentQuarterInstant401987000000JPY
Treasury stockPrior1YearInstant-61504000000JPY
Treasury stockCurrentQuarterInstant-61376000000JPY
Shareholders equityPrior1YearInstant385675000000JPY
Shareholders equityCurrentQuarterInstant393491000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant34211000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant36568000000JPY
Revaluation reserve for landPrior1YearInstant-4750000000JPY
Revaluation reserve for landCurrentQuarterInstant-4750000000JPY
Foreign currency translation adjustmentPrior1YearInstant662000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant1750000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1887000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1691000000JPY
Valuation and translation adjustmentsPrior1YearInstant32011000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant35258000000JPY
Non controlling interestsPrior1YearInstant375000000JPY
Non controlling interestsCurrentQuarterInstant306000000JPY
Net assetsPrior1YearInstant418062000000JPY
Net assetsCurrentQuarterInstant429056000000JPY
Liabilities and net assetsPrior1YearInstant1141717000000JPY
Liabilities and net assetsCurrentQuarterInstant1193426000000JPY
Net salesPrior1YTDDuration1100786000000JPY
Net salesCurrentYTDDuration1138310000000JPY
Cost of salesPrior1YTDDuration1020989000000JPY
Cost of salesCurrentYTDDuration1050318000000JPY
Gross profitPrior1YTDDuration79796000000JPY
Gross profitCurrentYTDDuration87992000000JPY
Selling general and administrative expensesPrior1YTDDuration72707000000JPY
Selling general and administrative expensesCurrentYTDDuration73109000000JPY
Operating incomePrior1YTDDuration7089000000JPY
Operating incomeCurrentYTDDuration14882000000JPY
Interest income noiPrior1YTDDuration77000000JPY
Interest income noiCurrentYTDDuration65000000JPY
Dividends income noiPrior1YTDDuration924000000JPY
Dividends income noiCurrentYTDDuration678000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration395000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration633000000JPY
Other noiPrior1YTDDuration527000000JPY
Other noiCurrentYTDDuration700000000JPY
Non operating incomePrior1YTDDuration1925000000JPY
Non operating incomeCurrentYTDDuration2077000000JPY
Interest expenses noePrior1YTDDuration29000000JPY
Interest expenses noeCurrentYTDDuration21000000JPY
Rent expenses on real estates noePrior1YTDDuration112000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass